Last10K.com

Generex Biotechnology Corp (GNBT) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, July 31, 2018

Generex Biotechnology Corp

HISTORY TOOLS
CIK: 1059784 Ticker: GNBT
Document and Entity Information - USD ($)
12 Months Ended
Jul. 31, 2018
Oct. 26, 2018
Document And Entity Information  
Entity Registrant NameGENEREX BIOTECHNOLOGY CORP 
Entity Central Index Key0001059784 
Current Fiscal Year End Date--07-31 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Shell Companyfalse 
Entity Emerging Growth Companyfalse 
Trading SymbolGNBT 
Document Type10-K 
Amendment Flagfalse 
Document Period End DateJul. 31, 2018 
Document Fiscal Period FocusFY 
Document Fiscal Year Focus2018 
Entity Well-Known Seasoned IssuerNo 
Entity Voluntary FilersNo 
Entity Current Reporting StatusYes 
Entity Common Stock, Shares Outstanding 1,065,093
Entity Public Float$ 2,200,000 

View differences made from one year to another to evaluate Generex Biotechnology Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Generex Biotechnology Corp.

Continue

Assess how Generex Biotechnology Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Generex Biotechnology Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity (Deficiency)
Consolidated Statements Of Operations And Comprehensive Loss
Acquisition Of Hema Diagnostics Systems, Llc
Acquisition Of Hema Diagnostics Systems, Llc (Details Narrative)
Acquisition Of Hema Diagnostics Systems, Llc (Tables)
Acquisition Of Hema Diagnostics Systems, Llc - Net Purchase Price Of Hds (Details)
Acquisition Of Hema Diagnostics Systems, Llc - Purchase Price Allocation Of Hds (Details)
Acquisition Of Pharmacies
Acquisition Of Pharmacies (Details Narrative)
Acquisition Of Pharmacies (Tables)
Acquisition Of Pharmacies - Purchase Price Allocated As Of Acquisition Date (Details)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Convertible Note Payable
Convertible Note Payable (Details Narrative)
Fair Value Assumptions Used In Accounting For Call Options (Details)
Fair Value Assumptions Used In Accounting For Warrants (Details)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Tables)
Goodwill And Intangible Assets - Changes In The Carrying Amount Of Goodwill And Other Intangible Assets (Details)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Deferred Income Taxes (Details)
Income Taxes - Reconciliation Of Effective Tax Rate (Details)
Loan From Related Parties (Details Narrative)
Loan Payable
Loan Payable (Details Narrative)
Loans From Related Parties
Net (Loss) / Income Per Share (€Œeps”)
Net (Loss) / Income Per Share (€Œeps”) (Tables)
Net (Loss) / Income Per Share (€Œeps”) - Computation Of Diluted Eps (Details)
Net (Loss)/ Income Per Share (€Œeps”) (Details Narrative)
Organization Of Business And Going Concern
Organization Of Business And Going Concern (Details Narrative)
Patents
Patents (Details Narrative)
Patents (Tables)
Patents - Costs And Accumulated Amortization Of Patents (Details)
Property And Equipment
Property And Equipment (Details Narrative)
Property And Equipment (Tables)
Property And Equipment - Long Lived Assets (Details)
Segment Information
Segment Information (Details)
Segment Information (Tables)
Stock-Based Compensation
Stock-Based Compensation (Details Narrative)
Stock-Based Compensation (Tables)
Stock-Based Compensation - Common Stock Options Granted, Forfeited Or Expired And Exercised (Details)
Stock-Based Compensation - Information On Stock Options Outstanding (Details)
Stockholders' Deficiency
Stockholders' Deficiency (Details Narrative)
Stockholders' Deficiency (Tables)
Stockholders' Deficiency - Schedule Of Warrants Exercised (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Generex Biotechnology Corp provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: GNBT
CIK: 1059784
Form Type: 10-K Annual Report
Accession Number: 0001607062-18-000361
Submitted to the SEC: Fri Oct 26 2018 1:29:43 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Tuesday, July 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/gnbt/0001607062-18-000361.htm